Scholarlink

Background <p>Multiple sclerosis (MS) is associated with increased cardiovascular morbidity, yet the magnitude of myocardial infarction (MI) risk remains uncertain. With newer cohort studies and advances in meta-analytic methods, an updated evidence synthesis is warranted. We conducted a systematic review and meta-analysis to quantify MI risk in MS patients.</p> Methods <p>We searched PubMed, Embase, and Scopus from inception through December 2025 for observational studies comparing MI risk between adults with MS and controls. Random-effects meta-analysis using restricted maximum likelihood estimation with Hartung-Knapp-Sidik-Jonkman adjustment was performed. Risk of bias was assessed using the Newcastle-Ottawa Scale, and certainty of evidence was evaluated using GRADE. Mendelian randomization evidence was synthesized separately.</p> Results <p>Twenty cohorts from 18 studies were included. Seven cohorts (97,996 MS patients; 824,497 controls) contributed to the primary meta-analysis after excluding one study due to overlapping populations. MS patients had significantly increased MI risk (RR 1.70, 95% CI: 1.57–1.85; <i>p</i> &lt; 0.0001) with moderate heterogeneity (I²=40.3%). The 95% prediction interval (1.60–1.81) indicated consistently elevated risk across settings. Secondary analyses showed increased stroke risk (RR 1.66, 95% CI: 1.01–2.73). Subgroup analyses revealed no significant differences by geographic region (<i>p</i> = 0.066), adjustment status (<i>p</i> = 0.45), or effect measure type (<i>p</i> = 0.79). Leave-one-out sensitivity analysis confirmed robust findings (RR range: 1.69–1.76). Mendelian randomization evidence showed a weak genetic association (OR 1.03, 95% CI: 1.00-1.06). GRADE certainty was very low.</p> Conclusions <p>MS patients have a 70% increased risk of MI compared to individuals without MS. This risk elevation, comparable to other autoimmune conditions with established cardiovascular screening guidelines, supports the need for enhanced cardiovascular surveillance in MS populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk of myocardial infarction in patients with multiple sclerosis: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月13日

查看全文
  • Shankar Biswas,
  • Sindhu Vasireddy,
  • Yashasvi Srivastava,
  • Ayman Hamadttu

摘要

Background

Multiple sclerosis (MS) is associated with increased cardiovascular morbidity, yet the magnitude of myocardial infarction (MI) risk remains uncertain. With newer cohort studies and advances in meta-analytic methods, an updated evidence synthesis is warranted. We conducted a systematic review and meta-analysis to quantify MI risk in MS patients.

Methods

We searched PubMed, Embase, and Scopus from inception through December 2025 for observational studies comparing MI risk between adults with MS and controls. Random-effects meta-analysis using restricted maximum likelihood estimation with Hartung-Knapp-Sidik-Jonkman adjustment was performed. Risk of bias was assessed using the Newcastle-Ottawa Scale, and certainty of evidence was evaluated using GRADE. Mendelian randomization evidence was synthesized separately.

Results

Twenty cohorts from 18 studies were included. Seven cohorts (97,996 MS patients; 824,497 controls) contributed to the primary meta-analysis after excluding one study due to overlapping populations. MS patients had significantly increased MI risk (RR 1.70, 95% CI: 1.57–1.85; p < 0.0001) with moderate heterogeneity (I²=40.3%). The 95% prediction interval (1.60–1.81) indicated consistently elevated risk across settings. Secondary analyses showed increased stroke risk (RR 1.66, 95% CI: 1.01–2.73). Subgroup analyses revealed no significant differences by geographic region (p = 0.066), adjustment status (p = 0.45), or effect measure type (p = 0.79). Leave-one-out sensitivity analysis confirmed robust findings (RR range: 1.69–1.76). Mendelian randomization evidence showed a weak genetic association (OR 1.03, 95% CI: 1.00-1.06). GRADE certainty was very low.

Conclusions

MS patients have a 70% increased risk of MI compared to individuals without MS. This risk elevation, comparable to other autoimmune conditions with established cardiovascular screening guidelines, supports the need for enhanced cardiovascular surveillance in MS populations.